Form 4: Pfizer SVP & Controller Jennifer B. Damico Reports Stock Transactions
SEC Form 4 Filing
Jennifer B. Damico, SVP & Controller at Pfizer Inc., reports the earn-out and subsequent transactions related to stock appreciation rights.
Summary
- On February 27, 2025, Jennifer B. Damico, SVP & Controller of Pfizer Inc., engaged in transactions involving common stock and stock appreciation rights.
- Damico earned out 22,416 stock appreciation rights at a price of $31.31.
- 553 shares were withheld to satisfy tax obligations related to the earn-out of the stock appreciation rights at $26.1.
- 20,994 shares were withheld to cover the payment of the exercise price in connection with the earn-out of stock appreciation rights at $26.06.
- Following these transactions, Damico directly owns 9,516 shares of Pfizer common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel at Pfizer.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership of shares.
- The transactions are part of the executive compensation plan, impacting Jennifer B. Damico.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of earliest transaction: earn-out of stock appreciation rights, withholding of shares for tax obligations and exercise price. |
| 03/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.